Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?

PARP inhibitors, CDK4/6 inhibitors, immunotherapy, and SERDS: Can you select optimal treatments for early breast cancer (EBC)? And what might be the consensus at St. Gallen?    Credit available for this activity expires: 03/15/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989483?ecd=bdc_podcast_libsyn_mscpedu